Home Awareness CHMP Grants Favorable Opinion: Bristol Myers Melanoma
Awareness

CHMP Grants Favorable Opinion: Bristol Myers Melanoma

Bristol Myers Squibb announces that the European Medicines Agency’s CHMP has recommended approval of Opdivo as an adjuvant therapy for patients 12 years of age and older with completely resected stage IIB or IIC melanoma.

This positive opinion is based on safety and efficacy results from the Phase 3 CheckMate -76K trial, in which, with a minimum follow-up of 7.8 months, Opdivo reduced the risk of recurrence or death by 58% compared to placebo.

These results were presented at the 2022 annual meeting of the Society for Melanoma Research (SMR). The European Commission, which has the power to approve medicines in the European Union, will now review the CHMP recommendation.

This article is originally published on boursorama.com

Related Articles

Awareness

OPEC cuts demand forecast as rival production surges

OPEC lowers its forecast for global oil demand in the coming years,...

Awareness

Borrell landed in Beirut ahead of a two-day visit

The head of European Union (EU) diplomacy, Josep Borrell, arrived in Beirut...

Awareness

Five dead in Israeli strike in West Bank, Palestinian Red Crescent announces

New deadly bombardment by the Israeli army in the West Bank. The...

Awareness

Slovenian EU Commissioner’s choice rejected due to pressure for more women

Tomaž Vesel apparently withdrew after Ursula von der Leyen pushed for gender...